Welcome to our dedicated page for Evolus SEC filings (Ticker: EOLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Jeuveau sales move the needle at Evolus shouldn’t require wading through hundreds of pages of SEC text. Investors typically start with the Evolus quarterly earnings report 10-Q filing to see unit volumes, gross margin on the cash-pay aesthetic drug, and R&D outlays for next-generation toxins. Others jump straight to Evolus insider trading Form 4 transactions to gauge physician-founder and executive confidence. Whatever your starting point, our platform streamlines the journey.
Every new document lands here in real time�Evolus Form 4 insider transactions real-time, 8-K product-recall notices, or that detailed Evolus annual report 10-K simplified. Stock Titan’s AI reads the fine print for you, surfacing Jeuveau safety disclosures, patent-expiry timelines, and regional sales splits. It also answers the questions people actually ask: “understanding Evolus SEC documents with AI� or “Evolus proxy statement executive compensation�.
Need practical use cases? Compare quarter-over-quarter international revenue in one click, set alerts for Evolus executive stock transactions Form 4, or skim an AI synopsis of the latest Evolus 8-K material events explained. Our summaries strip out legalese, so you get Evolus SEC filings explained simply—from earnings report filing analysis to insider buying patterns—without missing a footnote. Insight in minutes, not hours.
Insider sale under 10b5-1 plan: Tomoko Yamagishi-Dressler, Chief Marketing Officer and director at Evolus, Inc. (EOLS), reported the sale of 5,722 shares of the company's common stock on 08/22/2025 at a price of $7.51 per share. After the transaction, the reporting person beneficially owned 89,949 shares. The filing indicates the sale was made pursuant to a Rule 10b5-1 trading plan and that the shares sold were required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units.
Form and signature: The Form 4 was executed by an attorney-in-fact on behalf of the reporting person and includes the standard certification language required by Section 16 filings.
Stewart Brady, a director of Evolus, Inc. (EOLS), purchased 30,000 shares of the issuer's common stock on 08/15/2025 at a weighted average price of $6.8162 per share, increasing his beneficial ownership to 88,629 shares. The Form 4 reports the shares were bought in multiple trades at prices ranging from $6.7699 to $6.82, and the filing was signed by Jeffrey J. Plumer as attorney-in-fact on 08/18/2025. The transaction is reported as a purchase and the ownership is listed as direct.
Timothy P. Lynch reported beneficial ownership of 4,094,489 shares of Evolus, Inc. common stock, representing 6.3% of the class based on 64,685,419 shares outstanding as of August 1, 2025. The filing shows Mr. Lynch holds 3,492,130 shares with sole voting and dispositive power and 602,359 shares with shared voting and dispositive power. The Schedule identifies the issuer's principal executive offices at 520 Newport Center Drive, Newport Beach, California.
The filing is a Schedule 13G and includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer. The reporting person’s address is listed as 70 SW Century Dr, STE 100 PMB 1257, Bend, OR 97702, and the signature is dated 08/15/2025.
Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 2,474,843 shares of Evolus, Inc. common stock, representing 3.8% of the outstanding class based on 64,685,419 shares outstanding as stated in the filing. The holdings are reported as shared voting and shared dispositive power; none of the Reporting Persons claim sole voting or sole dispositive power. The filing states the Master Fund directly holds the shares and Perceptive Advisors acts as its investment manager, with Mr. Edelman as managing member.
Caligan Partners LP and its managing partner David Johnson filed a Schedule 13G reporting shared beneficial ownership of 3,341,970 shares of Evolus, Inc. common stock, representing 5.2% of the class based on 64,475,589 shares outstanding as of May 2, 2025. The reporting persons state the shares are held by Caligan Partners Master Fund LP and a managed account and are owned in the ordinary course of business, not to influence control of the company. Caligan is organized in Delaware and Mr. Johnson is a U.S. citizen. Principal business address for the filers is 780 Third Avenue, 30th Floor, New York, NY 10017.
FAQ
What is the current stock price of Evolus (EOLS)?
What is the market cap of Evolus (EOLS)?
